Search
formoterol/glycopyrrolate (Bevespi Aerosphere)
Indications:
- treatment of COPD
Dosage:
- twice daily metered dose inhaler
formoterol fumarate (4.8 ug). glycopyrrolate (9 ug).
Adverse effects:
- urinary tract infection (2.6% vs 2.3% with placebo)
- cough (4.0% vs 2.7% with placebo)
Mechanism of action:
- long-acting muscarinic antagonist/long-acting beta-2 agonist combination
Notes:
- FDA-approved April 27, 2016
- marketed by Atra-Zeneca
General
LABA/LAMA combination
References
- Brooks M
FDA Clears Bevespi Aerosphere for COPD.
Medscape. April 27, 2016
http://www.medscape.com/viewarticle/862554
Components
formoterol (Foradil, Perforomist)
glycopyrrolate (Robinul, Cuvposa, Qbrexza)